Identification

Name
Sulpiride
Accession Number
DB00391  (APRD00032)
Type
Small Molecule
Groups
Approved, Investigational
Description

A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)

Structure
Thumb
Synonyms
  • (+-)-Sulpiride
  • 5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide
  • Levosulpirida
  • Levosulpiride
  • Levosulpiridum
  • N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide
  • N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-O-anisamide
  • Sulpirid
  • Sulpirida
  • Sulpiridum
  • Sulpyrid
International/Other Brands
Bosnyl / Dogmatil / Dogmatyl / Dolmatil / Eglonyl / Espiride / Meresa / Modal
Categories
UNII
7MNE9M8287
CAS number
15676-16-1
Weight
Average: 341.426
Monoisotopic: 341.140926929
Chemical Formula
C15H23N3O4S
InChI Key
BGRJTUBHPOOWDU-UHFFFAOYSA-N
InChI
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
IUPAC Name
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
SMILES
CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O

Pharmacology

Indication

Sulpiride is indicated for the treatment of schizophrenia.

Pharmacodynamics

Sulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.

Mechanism of action

In contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, Sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 3
inhibitor
Human
Absorption

Sulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

6 to 8 hours

Clearance
Not Available
Toxicity

Sulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trism. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineSulpiride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineSulpiride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-Hydroxyhippuric acidThe risk or severity of adverse effects can be increased when 3-Hydroxyhippuric acid is combined with Sulpiride.Experimental
3,4-MethylenedioxyamphetamineSulpiride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineSulpiride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Sulpiride is combined with 7-Nitroindazole.Experimental
AcepromazineAcepromazine may increase the antipsychotic activities of Sulpiride.Approved, Vet Approved
AceprometazineAceprometazine may increase the antipsychotic activities of Sulpiride.Approved
AcetophenazineAcetophenazine may increase the antipsychotic activities of Sulpiride.Approved
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Acetyldigoxin.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Sulpiride.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alaproclate.Experimental
AlcuroniumAlcuronium may increase the anticholinergic activities of Sulpiride.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Sulpiride.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Allopregnanolone.Investigational
AlmasilateThe serum concentration of Sulpiride can be decreased when it is combined with Almasilate.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sulpiride.Approved, Investigational
AloglutamolThe serum concentration of Sulpiride can be decreased when it is combined with Aloglutamol.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sulpiride.Approved, Illicit, Investigational
AluminiumThe serum concentration of Sulpiride can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Sulpiride can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Sulpiride can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe therapeutic efficacy of Sulpiride can be increased when used in combination with Aluminum hydroxide.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amikacin.Approved, Investigational, Vet Approved
Aminohippuric acidThe risk or severity of adverse effects can be increased when Aminohippuric acid is combined with Sulpiride.Approved, Investigational
AmiodaroneThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Amiodarone.Approved, Investigational
AmisulprideSulpiride may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Sulpiride.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Sulpiride.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sulpiride.Approved
AmperozideAmperozide may increase the antipsychotic activities of Sulpiride.Experimental
AmphetamineSulpiride may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
Anisotropine MethylbromideAnisotropine Methylbromide may increase the anticholinergic activities of Sulpiride.Approved
AripiprazoleAripiprazole may increase the antipsychotic activities of Sulpiride.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Articaine.Approved
AsenapineAsenapine may increase the antipsychotic activities of Sulpiride.Approved
AtracuriumAtracurium may increase the anticholinergic activities of Sulpiride.Approved, Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the anticholinergic activities of Sulpiride.Approved
AtropineAtropine may increase the anticholinergic activities of Sulpiride.Approved, Vet Approved
AzaperoneAzaperone may increase the antipsychotic activities of Sulpiride.Investigational, Vet Approved
AzelastineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Azosemide is combined with Sulpiride.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Sulpiride.Approved
BarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Barbital.Illicit
BenactyzineBenactyzine may increase the anticholinergic activities of Sulpiride.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sulpiride.Approved
BenperidolBenperidol may increase the antipsychotic activities of Sulpiride.Approved, Investigational
BenzatropineBenzatropine may increase the anticholinergic activities of Sulpiride.Approved
BenzphetamineSulpiride may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
BenzthiazideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Sulpiride.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sulpiride is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Bepridil.Approved, Withdrawn
BezafibrateThe risk or severity of adverse effects can be increased when Bezafibrate is combined with Sulpiride.Approved, Investigational
BifeprunoxBifeprunox may increase the antipsychotic activities of Sulpiride.Investigational
BiperidenBiperiden may increase the anticholinergic activities of Sulpiride.Approved, Investigational
Bismuth subcitrate potassiumThe serum concentration of Sulpiride can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe serum concentration of Sulpiride can be decreased when it is combined with Bismuth subnitrate.Approved
BornaprineBornaprine may increase the anticholinergic activities of Sulpiride.Experimental
BrexpiprazoleBrexpiprazole may increase the antipsychotic activities of Sulpiride.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sulpiride.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulpiride.Approved, Investigational
BromoprideThe risk or severity of adverse effects can be increased when Bromopride is combined with Sulpiride.Approved, Investigational
BromperidolBromperidol may increase the antipsychotic activities of Sulpiride.Approved, Investigational
BrompheniramineBrompheniramine may increase the anticholinergic activities of Sulpiride.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sulpiride.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sulpiride.Approved, Investigational
BuprenorphineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Sulpiride is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sulpiride.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sulpiride.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Sulpiride.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butamben.Approved, Withdrawn
ButaperazineButaperazine may increase the antipsychotic activities of Sulpiride.Experimental
ButethalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sulpiride.Approved, Illicit, Vet Approved
ButylscopolamineButylscopolamine may increase the anticholinergic activities of Sulpiride.Approved, Investigational, Vet Approved
CabergolineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cabergoline.Approved
Calcium CarbonateThe therapeutic efficacy of Sulpiride can be increased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium silicateThe serum concentration of Sulpiride can be decreased when it is combined with Calcium silicate.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Sulpiride is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sulpiride.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Sulpiride.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineCariprazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Sulpiride.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Sulpiride.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sulpiride.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sulpiride.Approved, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Chlorphenamine.Approved
ChlorphenoxamineChlorphenoxamine may increase the anticholinergic activities of Sulpiride.Withdrawn
ChlorphentermineSulpiride may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the antipsychotic activities of Sulpiride.Experimental
ChlorpromazineChlorpromazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational, Vet Approved
ChlorprothixeneChlorprothixene may increase the antipsychotic activities of Sulpiride.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sulpiride.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Sulpiride.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sulpiride.Approved, Investigational
CisaprideThe risk or severity of adverse effects can be increased when Cisapride is combined with Sulpiride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Sulpiride is combined with Citalopram.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Sulpiride.Approved
ClindamycinClindamycin may increase the antipsychotic activities of Sulpiride.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Sulpiride.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Sulpiride is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sulpiride.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Sulpiride.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Sulpiride.Approved
ClopenthixolClopenthixol may increase the antipsychotic activities of Sulpiride.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sulpiride.Approved, Illicit
ClothiapineClothiapine may increase the antipsychotic activities of Sulpiride.Experimental
ClozapineClozapine may increase the antipsychotic activities of Sulpiride.Approved
CocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sulpiride.Approved, Illicit
CyamemazineCyamemazine may increase the antipsychotic activities of Sulpiride.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Sulpiride.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sulpiride.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Sulpiride.Experimental
CyclopentolateCyclopentolate may increase the anticholinergic activities of Sulpiride.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cymarin.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Sulpiride.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Sulpiride.Approved, Investigational
DapiprazoleDapiprazole may increase the antipsychotic activities of Sulpiride.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dapoxetine.Investigational
DarifenacinDarifenacin may increase the anticholinergic activities of Sulpiride.Approved, Investigational
DeclopramideThe risk or severity of adverse effects can be increased when Declopramide is combined with Sulpiride.Investigational
DelamanidSulpiride may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Sulpiride.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Sulpiride.Approved, Investigational
DeslanosideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Deslanoside.Approved
DesloratadineDesloratadine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Detomidine.Vet Approved
DeutetrabenazineSulpiride may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sulpiride.Approved
DexetimideDexetimide may increase the anticholinergic activities of Sulpiride.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineSulpiride may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sulpiride.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Sulpiride.Approved, Illicit, Investigational, Vet Approved
DicyclomineDicyclomine may increase the anticholinergic activities of Sulpiride.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Sulpiride is combined with Diethyl ether.Experimental
DiethylpropionSulpiride may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DiethyltoluamideThe risk or severity of adverse effects can be increased when Diethyltoluamide is combined with Sulpiride.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Sulpiride.Approved, Illicit
DigitoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Sulpiride is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sulpiride.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sulpiride.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sulpiride.Approved, Illicit
DixyrazineDixyrazine may increase the antipsychotic activities of Sulpiride.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Doramectin.Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dotarizine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Sulpiride.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Sulpiride is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Illicit
DroperidolDroperidol may increase the antipsychotic activities of Sulpiride.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ecgonine.Experimental, Illicit
EcopipamEcopipam may increase the antipsychotic activities of Sulpiride.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Sulpiride.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sulpiride.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Eltanolone.Investigational
EmeproniumEmepronium may increase the anticholinergic activities of Sulpiride.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sulpiride.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Sulpiride.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Eperisone.Approved, Investigational
EpitizideThe risk or severity of adverse effects can be increased when Epitizide is combined with Sulpiride.Experimental
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulpiride.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulpiride.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sulpiride.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Sulpiride is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Sulpiride.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sulpiride.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sulpiride.Approved, Investigational
EtanautineEtanautine may increase the anticholinergic activities of Sulpiride.Experimental
EthanolSulpiride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sulpiride.Approved, Illicit, Withdrawn
EthopropazineEthopropazine may increase the anticholinergic activities of Sulpiride.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sulpiride.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Sulpiride.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sulpiride.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineEtybenzatropine may increase the anticholinergic activities of Sulpiride.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Sulpiride.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sulpiride.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Sulpiride.Approved
FencamfamineFencamfamine may increase the antipsychotic activities of Sulpiride.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sulpiride.Approved, Illicit, Investigational, Vet Approved
FesoterodineFesoterodine may increase the anticholinergic activities of Sulpiride.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Sulpiride.Approved, Investigational
FlavoxateFlavoxate may increase the anticholinergic activities of Sulpiride.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Sulpiride.Approved, Investigational
FluanisoneFluanisone may increase the antipsychotic activities of Sulpiride.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Sulpiride.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the antipsychotic activities of Sulpiride.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the antipsychotic activities of Sulpiride.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sulpiride.Approved, Illicit, Investigational
FluspirileneFluspirilene may increase the antipsychotic activities of Sulpiride.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Sulpiride.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Sulpiride.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Sulpiride.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Sulpiride.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sulpiride.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Sulpiride.Approved, Investigational
GallamineGallamine may increase the anticholinergic activities of Sulpiride.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the anticholinergic activities of Sulpiride.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Sulpiride.Approved, Illicit, Investigational
GepefrineSulpiride may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gepirone.Investigational
GitoformateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gitoformate.Experimental
GlutethimideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Glutethimide.Approved, Illicit
GlycopyrroniumGlycopyrronium may increase the anticholinergic activities of Sulpiride.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Sulpiride.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the antipsychotic activities of Sulpiride.Approved
HalothaneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Hexobarbital.Approved
HomatropineHomatropine may increase the anticholinergic activities of Sulpiride.Approved
HydrochlorothiazideThe risk or severity of orthostatic hypotension can be increased when Hydrochlorothiazide is combined with Sulpiride.Approved, Vet Approved
HydrocodoneSulpiride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sulpiride.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sulpiride.Approved, Illicit
HydrotalciteThe serum concentration of Sulpiride can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
HydroxyamphetamineSulpiride may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
HyoscyamineHyoscyamine may increase the anticholinergic activities of Sulpiride.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sulpiride.Approved, Investigational
IloperidoneIloperidone may increase the antipsychotic activities of Sulpiride.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Sulpiride.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Sulpiride.Approved
IndalpineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Sulpiride.Approved
IndiplonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Sulpiride.Withdrawn
Iofetamine I-123Sulpiride may decrease the stimulatory activities of Iofetamine I-123.Approved
IpratropiumIpratropium may increase the anticholinergic activities of Sulpiride.Approved
IsocarboxazidThe therapeutic efficacy of Sulpiride can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Sulpiride.Approved, Vet Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Sulpiride.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Sulpiride.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketobemidone.Approved, Investigational
LamotrigineLamotrigine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lanatoside C.Experimental
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Sulpiride.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Sulpiride.Approved
LevodopaThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sulpiride.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Sulpiride.Approved, Investigational
LisdexamfetamineSulpiride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
Lithium cationLithium may increase the antipsychotic activities of Sulpiride.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Sulpiride can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Loprazolam.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sulpiride.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sulpiride.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lormetazepam.Approved
LoxapineLoxapine may increase the antipsychotic activities of Sulpiride.Approved
LurasidoneLurasidone may increase the antipsychotic activities of Sulpiride.Approved, Investigational
MacimorelinSulpiride may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MagaldrateThe serum concentration of Sulpiride can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe therapeutic efficacy of Sulpiride can be increased when used in combination with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Magnesium citrate.Approved
Magnesium hydroxideThe therapeutic efficacy of Sulpiride can be increased when used in combination with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium silicate.Approved
Magnesium sulfateThe therapeutic efficacy of Sulpiride can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe therapeutic efficacy of Sulpiride can be increased when used in combination with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sulpiride.Approved, Investigational
MazaticolMazaticol may increase the anticholinergic activities of Sulpiride.Experimental
MebicarThe risk or severity of adverse effects can be increased when Sulpiride is combined with Mebicar.Experimental
MecamylamineMecamylamine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Sulpiride.Approved
MedazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Sulpiride is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the antipsychotic activities of Sulpiride.Approved, Investigational
MephedroneSulpiride may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineSulpiride may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sulpiride.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Sulpiride.Approved, Vet Approved
MequitazineSulpiride may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineMesoridazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sulpiride.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Sulpiride.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineSulpiride may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethanthelineMethantheline may increase the anticholinergic activities of Sulpiride.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methaqualone.Illicit, Withdrawn
MethenamineThe risk or severity of adverse effects can be increased when Methenamine is combined with Sulpiride.Approved, Vet Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sulpiride.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sulpiride.Approved
MethotrimeprazineMethotrimeprazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineSulpiride may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethscopolamineMethscopolamine may increase the anticholinergic activities of Sulpiride.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sulpiride.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sulpiride.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenobarbital.Approved
Methylscopolamine bromideMethylscopolamine bromide may increase the anticholinergic activities of Sulpiride.Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Metildigoxin.Experimental
MetixeneMetixene may increase the anticholinergic activities of Sulpiride.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sulpiride.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride.Approved
MetyrosineSulpiride may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Sulpiride.Approved, Illicit
MidomafetamineSulpiride may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Sulpiride is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
MirtazapineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDASulpiride may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sulpiride.Approved, Investigational
MolindoneMolindone may increase the antipsychotic activities of Sulpiride.Approved
MoperoneMoperone may increase the antipsychotic activities of Sulpiride.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sulpiride.Approved, Investigational
MosapramineMosapramine may increase the antipsychotic activities of Sulpiride.Experimental
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sulpiride.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sulpiride.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Sulpiride.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nefazodone.Approved, Withdrawn
NeomycinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Neomycin.Approved, Vet Approved
NicardipineNicardipine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sulpiride.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Sulpiride.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sulpiride.Approved
OlanzapineOlanzapine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
OleandrinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oleandrin.Experimental, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sulpiride.Approved
OmeprazoleThe therapeutic efficacy of Sulpiride can be increased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Sulpiride.Approved
OpiumThe risk or severity of adverse effects can be increased when Sulpiride is combined with Opium.Approved, Illicit
OrphenadrineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantOsanetant may increase the antipsychotic activities of Sulpiride.Investigational
OtiloniumOtilonium may increase the anticholinergic activities of Sulpiride.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ouabain.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sulpiride.Approved
OxitropiumOxitropium may increase the anticholinergic activities of Sulpiride.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxybuprocaine.Approved, Investigational
OxybutyninOxybutynin may increase the anticholinergic activities of Sulpiride.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sulpiride.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sulpiride.Approved, Investigational, Vet Approved
OxypertineOxypertine may increase the antipsychotic activities of Sulpiride.Experimental
OxyphenoniumOxyphenonium may increase the anticholinergic activities of Sulpiride.Approved
PaliperidonePaliperidone may increase the antipsychotic activities of Sulpiride.Approved
PancuroniumPancuronium may increase the anticholinergic activities of Sulpiride.Approved
ParaldehydeSulpiride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
PenfluridolPenfluridol may increase the antipsychotic activities of Sulpiride.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sulpiride.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sulpiride.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the anticholinergic activities of Sulpiride.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
PerazinePerazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
PerospironePerospirone may increase the antipsychotic activities of Sulpiride.Approved
PerphenazinePerphenazine may increase the antipsychotic activities of Sulpiride.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sulpiride.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sulpiride.Approved
PhenglutarimidePhenglutarimide may increase the anticholinergic activities of Sulpiride.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenibut.Experimental
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sulpiride.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sulpiride.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenoxyethanol.Approved
PhentermineSulpiride may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Sulpiride.Approved, Vet Approved
PimozidePimozide may increase the antipsychotic activities of Sulpiride.Approved
PipamperonePipamperone may increase the antipsychotic activities of Sulpiride.Approved, Investigational
PipecuroniumPipecuronium may increase the anticholinergic activities of Sulpiride.Approved
PipotiazinePipotiazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
PirenzepinePirenzepine may increase the anticholinergic activities of Sulpiride.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Sulpiride.Approved
PiritramideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Piritramide.Approved, Investigational
PitolisantThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Sulpiride.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Sulpiride.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Sulpiride.Approved
PramipexoleThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Sulpiride can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Sulpiride.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Sulpiride.Approved
ProcaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Sulpiride.Approved, Investigational
ProchlorperazineProchlorperazine may increase the antipsychotic activities of Sulpiride.Approved, Vet Approved
ProcyclidineProcyclidine may increase the anticholinergic activities of Sulpiride.Approved
PromazinePromazine may increase the antipsychotic activities of Sulpiride.Approved, Vet Approved
PromethazinePromethazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Sulpiride.Approved
PropanididThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propanidid.Experimental
PropanthelinePropantheline may increase the anticholinergic activities of Sulpiride.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proparacaine.Approved, Vet Approved
PropericiazinePropericiazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
PropiverinePropiverine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Sulpiride.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propoxycaine.Approved
ProscillaridinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proscillaridin.Experimental
ProthipendylProthipendyl may increase the antipsychotic activities of Sulpiride.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sulpiride.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Sulpiride is combined with PSD502.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Sulpiride.Approved
PyrantelThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pyrantel.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Sulpiride.Approved, Illicit
QuetiapineQuetiapine may increase the antipsychotic activities of Sulpiride.Approved
QuinagolideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Quinagolide.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Sulpiride.Approved
QuinidineQuinidine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Quinisocaine.Experimental
RacloprideRaclopride may increase the antipsychotic activities of Sulpiride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Sulpiride.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sulpiride.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sulpiride.Approved
RemoxiprideRemoxipride may increase the antipsychotic activities of Sulpiride.Approved, Withdrawn
ReserpineReserpine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Sulpiride.Approved, Investigational
RisperidoneRisperidone may increase the antipsychotic activities of Sulpiride.Approved, Investigational
RitanserinRitanserin may increase the antipsychotic activities of Sulpiride.Investigational
RitobegronSulpiride may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sulpiride.Approved
RomifidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Romifidine.Vet Approved
RopiniroleThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sulpiride.Approved
RotigotineSulpiride may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sulpiride.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sulpiride.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sulpiride.Approved
ScopolamineScopolamine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sulpiride.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Sulpiride.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sepranolone.Investigational
SertindoleSertindole may increase the antipsychotic activities of Sulpiride.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sulpiride.Approved, Vet Approved
Sodium bicarbonateThe serum concentration of Sulpiride can be decreased when it is combined with Sodium bicarbonate.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
SolifenacinSolifenacin may increase the anticholinergic activities of Sulpiride.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Sulpiride.Approved
SucralfateThe serum concentration of Sulpiride can be decreased when it is combined with Sucralfate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sulpiride.Approved, Investigational
SultoprideSultopride may increase the antipsychotic activities of Sulpiride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Sulpiride.Approved, Investigational
SuvorexantSulpiride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Sulpiride.Approved, Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Sulpiride.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sulpiride.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Terodiline.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sulpiride.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the antipsychotic activities of Sulpiride.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetrodotoxin.Investigational
ThalidomideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiopental.Approved, Vet Approved
ThiopropazateThiopropazate may increase the antipsychotic activities of Sulpiride.Experimental
ThioproperazineThioproperazine may increase the antipsychotic activities of Sulpiride.Approved
ThioridazineThioridazine may increase the antipsychotic activities of Sulpiride.Approved, Withdrawn
ThiothixeneThiothixene may increase the antipsychotic activities of Sulpiride.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Sulpiride.Approved, Investigational
TiaprideTiapride may increase the antipsychotic activities of Sulpiride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tilidine.Experimental
TiotropiumTiotropium may increase the anticholinergic activities of Sulpiride.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Sulpiride.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sulpiride.Approved, Withdrawn
TolterodineTolterodine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Sulpiride.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride.Approved
TramadolTramadol may increase the anticholinergic activities of Sulpiride.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Sulpiride.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Sulpiride.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trichloroethylene.Approved
TrifluoperazineTrifluoperazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
TrifluperidolTrifluperidol may increase the antipsychotic activities of Sulpiride.Experimental
TriflupromazineTriflupromazine may increase the antipsychotic activities of Sulpiride.Approved, Vet Approved
TrihexyphenidylTrihexyphenidyl may increase the anticholinergic activities of Sulpiride.Approved
TrimebutineTrimebutine may increase the anticholinergic activities of Sulpiride.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trimethadione.Approved
TrimethaphanTrimethaphan may increase the anticholinergic activities of Sulpiride.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sulpiride.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Sulpiride.Approved
TromethamineThe serum concentration of Sulpiride can be decreased when it is combined with Tromethamine.Approved
TropatepineTropatepine may increase the anticholinergic activities of Sulpiride.Experimental
TropicamideTropicamide may increase the anticholinergic activities of Sulpiride.Approved, Investigational
TrospiumTrospium may increase the anticholinergic activities of Sulpiride.Approved
TubocurarineTubocurarine may increase the anticholinergic activities of Sulpiride.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Sulpiride.Approved
Valproic AcidThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Valproic Acid.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sulpiride.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Venlafaxine.Approved
VeraliprideVeralipride may increase the antipsychotic activities of Sulpiride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Sulpiride.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Sulpiride.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sulpiride.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Sulpiride.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the antipsychotic activities of Sulpiride.Approved
ZoaleneThe risk or severity of adverse effects can be increased when Zoalene is combined with Sulpiride.Vet Approved
ZolazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sulpiride.Approved, Investigational
ZolpidemSulpiride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sulpiride.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Sulpiride.Approved
ZotepineZotepine may increase the antipsychotic activities of Sulpiride.Approved, Investigational, Withdrawn
ZuclopenthixolZuclopenthixol may increase the antipsychotic activities of Sulpiride.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014535
KEGG Drug
D01226
PubChem Compound
5355
PubChem Substance
46504855
ChemSpider
5162
BindingDB
11638
ChEBI
32168
ChEMBL
CHEMBL26
Therapeutic Targets Database
DAP000310
PharmGKB
PA164745485
IUPHAR
958
Guide to Pharmacology
GtP Drug Page
Wikipedia
Sulpiride
ATC Codes
N05AL01 — SulpirideN05AL07 — Levosulpiride
MSDS
Download (57 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceIndigestion1
2, 3CompletedTreatmentAcute Agitation1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedTreatmentSchizophrenic Disorders1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedTreatmentPhysiology, Ocular / Regional Blood Flow1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)178 dec °CPhysProp
water solubility2280 mg/LNot Available
logP0.57HOEGBERG,T ET AL. 1986
Caco2 permeability-6.16ADME Research, USCD
pKa9.12EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.537 mg/mLALOGPS
logP1.2ALOGPS
logP0.22ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)10.24ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.73 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity88.63 m3·mol-1ChemAxon
Polarizability36.18 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9444
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7319
P-glycoprotein inhibitor INon-inhibitor0.857
P-glycoprotein inhibitor IINon-inhibitor0.8994
Renal organic cation transporterNon-inhibitor0.7685
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.54
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9656
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9409
Ames testNon AMES toxic0.6229
CarcinogenicityNon-carcinogens0.7139
BiodegradationNot ready biodegradable0.8542
Rat acute toxicity1.8612 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8546
hERG inhibition (predictor II)Inhibitor0.549
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0109000000-838e3fc396f400ef6f4b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-2901000000-15575a206ad43d931d6a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-3900000000-b83b6287d83301602f00
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a6r-8900000000-5a447dc363e7b3d43351
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9200000000-0a29790b32c5ae5e192a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9000000000-32eb95f9c75cc8d8ee85
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0009000000-b451c07c9adbe534b75c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ox-0049000000-eaadc21e5bafdd34a66e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-16b776d58e4e2dbc163e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-9fda88d7482dee887457
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0009000000-338379e29df68a5396b7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0209000000-d61c87359158078fa846
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-2931000000-6a28d0dd33433a572e50
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-4940000000-dcee56e4387108740566
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-8960000000-9f1a7605079446735287
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03e9-9620000000-c3bb475e828d5f8c88aa
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-3972000000-4f53a77ce37004c9eac3

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / Organosulfonamides / N-alkylpyrrolidines / Aminosulfonyl compounds / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds
show 5 more
Substituents
Benzenesulfonamide / Benzenesulfonyl group / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Organosulfonic acid amide / N-alkylpyrrolidine / Pyrrolidine
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, benzamides, N-alkylpyrrolidine (CHEBI:32168)

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185]
  2. Jaber M, Tison F, Fournier MC, Bloch B: Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Brain Res Mol Brain Res. 1994 Apr;23(1-2):14-20. [PubMed:7518029]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Lipina TV, Vishnivetskaia GB: [Effect of sulpiride on immobility reflex and pinch-induced catalepsy in CBA/Lac male mice with various social status]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2009 Jul-Aug;59(4):482-7. [PubMed:19795811]
  2. Collo G, Zanetti S, Missale C, Spano P: Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci. 2008 Oct;28(7):1231-40. doi: 10.1111/j.1460-9568.2008.06423.x. [PubMed:18973551]
Details
3. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]
Details
4. Carbonic anhydrase 3
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA3
Uniprot ID
P07451
Uniprot Name
Carbonic anhydrase 3
Molecular Weight
29557.215 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Vacca C, Maione S, Tozzi A, Marmo E: Benzamides and cholinesterases. Res Commun Chem Pathol Pharmacol. 1987 Feb;55(2):193-201. [PubMed:3823608]
  2. Dross K: [The relevance of anticholinesterase properties to toxicity and neuromuscular effects of sulpiride (author's transl)]. Arzneimittelforschung. 1977 Feb;27(2):404-6. [PubMed:577162]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:20